Advances in Dermatology: 2022 in Review
By Cather McKay MD, FAAD The past year brought many exciting advances in the field of dermatology. Below is a summary to help you continue providing up-to-date care for your patients. Psoriasis Topical options for psoriasis expanded this year to include tapinarof cream (Vtama), an aryl hydrocarbon receptor–modulating agent, and phosphodiesterase-4 (PDE4) inhibitor roflumilast cream (Zoryve). Additional indications for both are expected in the future. The approval of oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was welcomed in September, with trials in psoriatic arthritis ongoing 1 . IL-36 inhibitor spesolimab was also approved in September for generalized pustular psoriasis 2 . Risankizumab (Skyrizi) gained indications for psoriatic arthritis and Crohn’s disease this year. Apremilast (Otezla) is now indicated for all severities of psoriasis as of late 2021 and is in trials for palmoplantar pustulosis (PPP) 3 . Guidelines for psoriatic arthritis were publi...